Guangdong Meizhiyuan Biotechnology

Guangdong Meizhiyuan Biotechnology is a clinical-stage biopharmaceutical company headquartered in Guangzhou, China, dedicated to developing innovative peptide-based therapeutics for metabolic disorders and oncology. The company utilizes a proprietary technology platform to engineer multi-target agonists that mimic natural hormones to achieve superior clinical outcomes. Its lead program, MZY001, is a triple agonist targeting the GLP-1, GIP, and glucagon receptors, currently being evaluated in Phase 2 clinical trials for obesity and type 2 diabetes. Meizhiyuan's pipeline also includes several early-stage candidates aimed at addressing unmet needs in chronic metabolic conditions and cancer. The firm is led by a team of experienced scientists with expertise in peptide chemistry and metabolic disease biology. By focusing on multi-receptor signaling, the company aims to provide next-generation treatments with enhanced weight loss and glycemic control compared to existing therapies.